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Abstract: Genome sequencing is now a sufficiently mature and affordable technology  
for clinical use. Its application promises not only to transform clinicians’ diagnostic and 
predictive ability, but also to improve preventative therapies, surveillance regimes, and tailor 
patient treatment to an individual’s genetic make-up. However, as with any technological 
advance, there are associated fresh challenges. While some of the ethical, legal and social 
aspects resulting from the generation of data from genome sequencing are generic, several 
nuances are unique. Since the UK government recently announced plans to sequence the 
genomes of 100,000 Health Service patients, and similar initiatives are being considered 
elsewhere, a discussion of these nuances is timely and needs to go hand in hand with 
formulation of guidelines and public engagement activities around implementation of 
sequencing in clinical practice. 
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1. Introduction 
The speed by which a person’s genome can be analysed has increased phenomenally over recent 
years, while the attendant costs have plummeted. As a result, genetic testing is shifting from a targeted 
approach analysing specific genes based on particular symptoms or family histories to sequencing  
of an entire exome or genome (whole exome sequencing [WES], whole genome sequencing [WGS]). 
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Targeted approaches characteristically have a high yield for penetrant monogenic conditions; whole 
genome approaches have the potential to unravel a much larger proportion of genetic disease burden. 
Whole genome analyses, therefore, are likely not only to transform a clinician’s diagnostic and predictive 
ability, but also to improve preventative therapies, surveillance regimes, and tailor patient treatment to 
an individual’s genetic make-up. 
The improved diagnostic yields of genome sequencing are to be welcomed; however as with any 
technological advance there are associated fresh challenges. While the ethical, legal and social aspects 
resulting from the generation of data from genome sequencing are not unique, several nuances merit 
serious consideration. Since the UK government recently announced plans to sequence the genomes  
of 100,000 Health Service patients [1], and similar initiatives are being considered elsewhere,  
a discussion of these nuances is timely and needs to go hand in hand with formulation of guidelines 
and public engagement activities around the implementation of genome sequencing. Box 1 lists some 
of the ethical, legal, and social and practical issues that we consider merit consideration.
Box 1. Some of the overlapping ethical, legal, social and practical issues that need to be addressed 
as genome analysis enters clinical practice. 
Complexity 
 Genome analysis can provide many different predictions about diagnoses, or susceptibilities to 
conditions. However, it will do so with varying degrees of certainty or confidence intervals 
around the predictions. Such predictions are likely to change substantially over time as 
evidence about epistatic factors accumulates.
 Providing consent to genomic testing is therefore complex. Should consent be sought to any 
answer that genome analysis might provide? Or should there be cut-off for levels of certainty? 
Or should a genome analysis be used solely to answering a current clinical question? Should 
some results be staged? (e.g., risk of adult onset conditions diagnosed in children?)
Familial Aspects 
 Although genomic information is on the one hand very personal, on the other, it may be 
relevant to relatives who have not sought medical advice but may be identified as being at risk 
from the results in another person. How can health services best record, store and 
communicate such familial information? 
Re-Contacting/Follow Up Policies 
 Who should be re-contacted and when, in the light of evolving knowledge? Who might be liable 
if a patient remains unaware of new evidence and therefore interpretation of previous test results? 
Data Management 
 What should be stored: the DNA sample, the DNA sequence, the interpretation of the 
sequence? Or combinations of these? What is to be stored in medical record systems, and how 
can these be compliant with relevant data protection—and other—legislation? How can/should 
these be linked with biobank or research databases, and how can the security issues around 
identifiable data best be managed? 
Research/Clinical Divide 
 The traditional route of research to clinic evolution is not necessarily applicable in rapidly 
evolving technologies. 
Public Perceptions of Genetics 
 Currently, this is often thought as a clear cut, or deterministic result than there is evidence for. 
 Analytical validity not the same as clinical validity or utility; $1000 genome analysis is 
a reality soon, yet the cost of interpretation is much greater. 
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2. The Promise of Whole Genome Analysis 
Genetic testing has traditionally been restricted to analysing small numbers of genes usually picked 
on the basis of a high prior probability of being mutated. However, this approach has several limitations. 
Firstly, many inherited diseases are genetically heterogeneous and sequential mutational analysis of 
individual genes is slow and expensive. Secondly, while subsets of some common diseases can be caused 
by mutations in a single gene, traditional methods of selecting whom to test on basis of disease 
characteristics or family history are crude and have a high false negative rate. Finally, analysis may not 
ultimately be diagnostic if the disease is a consequence of a hitherto unknown disease-causing gene. 
Collectively these issues make whole genome approaches at competitive prices an attractive proposition. 
Most next-generation sequencing (NGS) technologies are based on the fragmentation of genomic 
DNA with the oversampling of reads providing the necessary linking information for whole-genome 
assembly algorithms. For analysis of a gene to be of diagnostic quality using NGS there needs to be 
sufficient read depth for any mutation to be called with a high degree of confidence. While WGS or 
WES typically provide good overall coverage for most regions of the genome, for other regions it may 
be poor; sequencing some regions of the genome is problematic because of repetitive sequence and 
other features leading to systematic error [2]. Such limitations have, in part, been the motivation for 
developing targeted sequencing approaches focusing on panels of genes relevant to specific diseases 
states; for example, cancer gene and nervous system disease panels. Such technical shortcomings are 
likely to be addressed in the near future so that a “one-stop-shop” test will replace the sequential 
approaches to genetic diagnoses which were time and labour intensive. 
3. Analytical Validity versus Interpretation of WGS Approaches 
Whilst the analytical validity of WGS approaches is high, and improving at a rapid pace, the 
clinical validity of the output from WGS is much more complex than commonly perceived and  
the utility has often been evaluated only in very small groups. There is much genome variation that is 
either: uninterpretable; probably benign; or only pathogenic in certain circumstances, for example,  
in the presence of as yet unknown epistatic factors. This gap between technological advances and  
the interpretation of any NGS output, is neatly encapsulated by the phrase “$1000 genome; $1 million 
interpretation [3], yet, little recognised in the popular discourse around whole genome technologies. 
In the clinical setting, certainly in the short term, diagnostic accuracy will therefore continue to 
depend on additional factors such as clinical history and, therefore, pre-test probability. Attempts to 
overcome these issues include use of gene panels or analyses of selected portions of the genetic code; 
an apparently anachronistic step in the evolution of whole genome approaches. However, if WGS 
approaches are to be used to answer clinical questions, some sort of filtering of sequence output will 
need to take place. Although targeted approaches are commonplace in health care, this has usually involved 
a targeting of the investigations. In WGS the targeting will have to be at the analysis stage—the results 
require targeted analysis—and this raises novel issues about what constitutes a result, what is disclosed 
to the patient, and what is recorded in a patient’s medical records.
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4. The Data Interpretation Problem 
Much of the misperception about the diagnostic value of genome sequencing results from  
an oversimplification in which it is assumed there is “a gene” for the condition, when in fact any 
increase in risk conferred by a mutation may be subtle, or only manifest in the context of specific 
genetic background or environmental exposure. For many common diseases there are multiple risk 
factors and while the identification of susceptibility genes has often provided novel insights in disease 
biology, their clinical utility in an individual may be very low because their predictive power in 
isolation is very poor. 
There is, however, also a risk of over-interpretation even for mutations with seemingly large effects. 
For affected patients where there is a strong prior probability of the gene mutation being causal 
because of a positive family history and or specific clinical phenotype, interpretation can be 
straightforward. However, if mutations are not fully penetrant, there will be carriers in the population 
who are healthy. Much of our knowledge about the penetrance of mutations to date is based on  
family data and, hence, suffers from ascertainment bias [4]. Without unbiased knowledge of the effect of 
mutations, interpretation at the population level will be inherently problematic. Whilst policies to 
restrict genetic testing to high risk populations were initially driven by budget restraints, and the more 
widespread availability of testing thought to be an advantage of declining costs, another consequence 
is that the interpretation of the clinical significance of a mutation is much more difficult if found 
without the ascertainment bias noted above. That is to say, predicting the effects of a novel BRCA2
mutation in the context of a strong family history of the mutation segregating with disease in the family, 
is far easier than when it is discovered in a population screen (see Box 2 for an illustrative example). 
Box 2. Difficulty of clinical interpretation of genomic findings in absence of clear clinical phenotype 
or family history.
A two-year old boy was investigated for “absence spells”. He had no loss of consciousness, was 
investigated in detail for epilepsy and no abnormalities were found. Paediatric cardiologists also found 
no abnormalities, his baseline ECG was defined as within normal limits and he had no family history 
(to 3rd degree relatives) of any cardiac problems. The cardiologist had been to a presentation about 
mainstreaming genetics and realised that long QT (LQT) interval gene carriers can be difficult to 
detect in childhood. He therefore requested genetic testing of LQT genes “to exclude LQT syndrome”. 
A LQT1—associated mutation was identified, described on the laboratory report as “highly likely to be 
pathogenic”. A reveal device was inserted but no abnormalities in his QT interval were recorded 
during subsequence “absence spells”. Nevertheless, it was thought appropriate to treat him with beta 
blockers. Cascade testing of his family revealed his three-year-old sister, father, paternal aunt (and her  
two children, aged four and eight) and paternal grandfather all carried the same mutation. Cardiac 
investigations of their phenotype, at rest, with exercise, and pharmacological challenge were normal or 
equivocal. All carriers in the family were prescribed beta blockade and two members of the family 
were referred for possible implantable cardiac defibrillator insertion. 
In Box 2 the assumption that this LQT1 mutation depicts a high future risk of clinical symptoms 
from LQT syndrome is based on the laboratory description of its likely pathogenicity and the previous 
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finding in families with symptomatic LQT. The intensive therapy is in part because the first presentation 
of LQT can be sudden cardiac death. However, this family was not ascertained on the basis of any 
relevant clinical symptoms and clear clinical predictions for the seven asymptomatic carriers are 
extremely difficult. However, if the mutation was found in a family with a segregating LQT 
phenotype, preventative therapy would be justifiable on clinical grounds. These cases serve to illustrate 
that the predictive powers of genetics require more than information about genotype, for the effects of 
any genotype are dependent on a range of other factors. Importantly, the penetrance of different 
mutations in the same gene can vary substantially and assigning a likelihood of a mutation being 
disease-causing will increasingly be based on the synthesis of multiple forms of evidence. 
5. Determining Clinical Utility of Sequence Variants 
The translation of genome sequence into medically actionable information is a key challenge. 
Without support from segregation in families, assigning pathogenicity can be problematic; notably 
large duplications, most synonymous and some missense mutations, intronic variants, and most 
variants in promoter and enhancers are particularly difficult to interpret. Predicting the functional 
consequences of variants which disrupt protein-coding sequence can also be challenging. A variant 
might affect a transcription factor binding site, a microRNA target site, affect RNA-splicing or 
stability or truncate a protein. Finally the issue of linkage disequilibrium (where benign variants lie 
close to a disease predisposing variant) can complicate interpretation of recurrent risk variants. 
Irrespective of whether animal models can adequately mimic human disease such model systems 
are inherently unsuited to determining the consequences of specific mutations as a routine activity. 
While yeast and cell line systems can be used to assess the functionality of DNA repair gene mutations 
the general applicability of such model systems is limited. In view of these factors increasing reliance 
will be placed on the implementation of in silico tools to infer the functional consequences of mutations. 
Although such algorithms can help to predict the likely pathogenicity of variants, often different tools 
conclude in opposite directions and without an established relationship between gene dysfunction and 
disease phenotype, robust risk prediction is problematic. 
6. The Need to Systematically Catalogue Sequence Variation with Phenotype 
Several initiatives are cataloguing and assigning pathogenicity to variants/mutations in various specific 
genes. Examples of such databases include InSiGHT (International Society for Gastrointestinal 
Hereditary Tumours Incorporated) [5], LoVd (Leiden open variant database) [6] Decipher [7] and 
DMuDB [8] (the diagnostic mutation database), and the Locus Reference Genomic Collaboration [9]. 
These resources provide health care professionals with valuable information for decision making 
processes. While published reports are valuable sources for such databases their stewardship depends 
heavily on the submission of individual variants and associated clinic-pathological data by sequencing 
laboratories using some form of incentivization. Currently these databases are limited to curation  
of restricted number of genes. Even here translating genomic sequence into medically actionable 
information can be highly time consuming. 
To meet the future needs, comprehensive resources with a far more overarching remit will need to 
be developed and maintained. This needs to be coupled with adoption of automated machine learning, 
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support vector machines and other technologies to create systematic and efficient mechanisms to assess 
the impact of variants found by genomic sequencing. All of this will require substantial investment 
before it becomes a reality and has not been factored into the $1000 genome analysis headlines. 
7. Diagnostics versus Population Screening 
Given the significant limitations to our current understanding of the impact of genetic variation, we 
believe that clinical genome sequencing should for now be focused on particular clinical presentations 
compatible with a genetic aetiology, rather than engaging in opportunistic population screening.  
For example, the identification of an APC mutation in a person with colonic polyposis is diagnostic 
and highly predictive for family members. In contrast the identification of variants, such as LQT1
described in Box 1, in a population screen do not have sufficient certainty to infer as much, resulting in 
difficult clinical management issues. Such contextual differences may be difficult to grasp if genetics 
is portrayed as being clear cut, and clinical interventions may therefore be offered without sufficient 
evidence for their benefit. 
Intelligent interrogation of genomic outputs in the clinic should initially therefore be restricted to 
specific genes or diseases for which there is a high prior likelihood of diagnosis. Any opportunistic 
screening should in the first instance be limited to known epistatic factors for particular conditions, e.g., 
low risk genes for breast cancer in the investigation of a family history of breast cancer, and formal 
evaluation of the benefits should not be leap frogged just because of the rapidly decreasing costs of  
the technologies involved. 
8. The Need for Large Scale Genotype-Phenotype Linkages 
Before more widespread population genome screening is to be contemplated, large-scale systematic 
and longitudinal investigation of variants in categorised populations would need to take place and their 
penetrance robustly determined. Depending on variant prevalence the ongoing international biobank 
sequencing projects are likely to provide a rich source of such data. Additionally, variants identified 
through clinical testing or research projects, could together with associated phenotypic information,  
be submitted to publicly accessible databases cataloguing genomic variation. Many of the current 
databases are however relatively ad hoc affairs and disease-specific. If the full potential of genomics  
is to be realised there is a need for the development of big data centres which have an overarching 
remit. However, the development and establishment of such initiatives brings with it the significant 
issue of data-storage and allied security requirements. These linkages will have to be undertaken 
within legislative frameworks relating to data protection within host countries and adapted to any 
changes to such legislation. For example, proposed changes by the European Commission to the data 
protection directive may have far reaching consequences for the gathering of such linkages [10]. 
9. The Need for Public-Professional Engagement 
In parallel with the acquisition and curation of genetic data there needs to be an ongoing dialogue 
with health care professionals and the public around understandings and interpretations of genomic 
data so that expectations of new WGS approaches are realistic and grounded in evidence. In the wake 
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of public anxiety around large scale databases, e.g., care.data in UK [11], this dialogue urgently needs 
to incorporate the importance of data sharing to realise the clinical utility of whole genome 
approaches. It also needs to incorporate the issues around shifting the point of targeting, as outlined  
in Section 3. For example, international recommendations suggest that children should not be offered 
genetic testing for adult-onset conditions (unless a result would alter their medical management). 
However, once such a result is available many would opine it should be disclosed, even if they would 
not have tested for it in the first place [12,13]. 
10. Incidental Findings 
Any broad, highly sensitive investigation has the ability to occasionally detect abnormalities that are 
incidental to the reason for the test. Whole genome approaches are much more likely to detect 
asymptomatic or silent abnormalities that have nothing to do with the current clinical reason for a test. 
Such findings have been variably termed “secondary”, “non-pertinent”, “unexpected” or “incidental” 
belying the fact that the appropriate adjective may vary according to the situation [14]. A genome test 
can, however, only have an incidental finding (IF) if it is used to answer, for example, a particular 
clinical question. If the question is “what are the abnormalities in this genome?” then there can be no IFs.
There has been much recent debate about the management of IFs in clinical applications of WG 
technologies [15–20]. The American College of Medical Genetics and Genomics (ACMG) produced 
guidelines that recommended the active search for particular IFs if using WGS/WES approaches [21]. 
The heated debate that ensued was largely focused on patient/parental choice regarding such IF 
searches with their purported “right not to know” being exercised by such guidance. A subsequent 
amendment now argues for decision about IF search to be made at the time of testing, but still 
recommends search for additional mutations not indicated by the clinical symptoms. The European 
Society of Human Genetics (ESHG) responded that WG approaches should be targeted to the clinical 
question, but there is still widespread debate about the management of IFs in practice and whether real 
up-front patient choice is feasible or preferable. 
11. Familial Consequences of IFs 
A family history of a particular disease usually means that unaffected relatives have some idea  
they too might be at risk. In contrast, if something is found incidentally there is unlikely to be 
awareness of the suspected condition. Furthermore, a new variant may only be found to be clinically 
significant once it has been studied alongside phenotypes in a family and the absence of a family 
history is likely to make the need for such cascade screening more difficult to comprehend. 
Furthermore, professionals may be uncertain what, if any, duties they have to alert relatives about risks 
that may only be clarified after cascade screening. 
12. Return of Results from Genomic Testing 
As the pace and scale of genetic testing increases, it is inevitable there will be less time to prepare 
individuals for potential test results. Since the implications of some variants, particularly IFs, may  
fall outside the expertise of the professional who requested the test, referral to another health care 
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professional may be necessary. This process is likely to add to anxiety of families burdened with 
unexpected genetic information and means that consent and disclosure practices become dissociated. 
Training in genomic medicine should be expanded to all medical specialties so that the complexities of 
genomic information can be adequately communicated but we do not underestimate the size of  
this task in a rapidly changing environment. We suggest that clinical genetic professionals, although 
relatively few in number, will need to take on greater liaison activities to facilitate this training. 
Opinions about disclosure of IFs vary, ranging from full disclosure to disclosing only those with 
established clinical significance, and/or which have an intervention can impact on disease. In reality 
clinically significant, because further investigations of the patient, and their relatives, may be required it 
can be extremely difficult to withhold details of IFs, even if a conclusion is that they are not to arrive at 
this conclusion. Even if the pathogenicity of an IF is established, disease onset may not be for many 
years. Hence robust mechanisms are required to identify, re-contact, and review family members when 
health care interventions become appropriate. Current health-care systems are, however ill-equipped to 
deal with the recording of familial information, future risks to health, or the monitoring of multiple 
family members. We consider that genome results need to be considered as a resource that can be 
accessed over time [22], rather than as one result that needs to be disclosed as one at the point of testing. 
13. Consent for Genome Testing 
Providing individuals with sufficient information in order to make decisions about investigations or 
interventions is a key element of good clinical practice. Achieving a balance between providing 
sufficient information but avoiding overload can be a challenge, especially for tests where multiple 
different outcomes are possible. Individuals need to understand what genome tests can reveal, but also 
that some degree of uncertainty is likely. The possible need to investigate relatives to assign 
pathogenicity of variants found is a difficult issue to incorporate into any consent process. Obtaining 
adequate consent to disclose an IF for which there is no prior suspicion on the basis of family history 
or symptoms is likewise problematic, especially if such an IF is unlikely to have clinical consequences 
for some time. All of this is set against a background of media coverage that generally portrays 
genetics as clear-cut and highly determinative. 
14. Is Personalised Medicine a Helpful Term to Promote Genomics? 
Although genomic analyses will help to stratify individuals into subpopulations with common 
characteristics so that particular variants might have greater predictive value, this is not the same as 
individualisation. A concern about describing genomics as leading to personalised medicine is that it 
may encourage views of genetic determinism or reductionism. There has been much professional and 
public discussion regarding which parts of a whole genome sequence should be communicated, with 
emotive discussions about rights to personal information. On the one hand there is a public perception 
that some form of medical paternalism might be exhibited where useful information would be 
withheld, on the other there is acceptance that most of the three billion letter output of a genome 
sequence has no personal clinical relevance [23]. Some advocate that anyone sequenced should have 
the right to be appraised of “all of” the test results, even if the clinical relevance is indeterminate. 
Genes 2014, 5 584
Whilst full disclosure is thought to respect a person’s autonomy it may do the opposite if it delivers 
outputs that are uninterpretable. 
15. Conclusions 
Whilst the technology of genome sequencing is now a sufficiently mature and affordable technology 
for it to be implemented clinically, significant challenges around interpretation and implementation 
remain. We believe that clinical genome analyses should be directed to delivering diagnoses for 
patients and that integration or linkage with biobanks and other research ventures will be crucial for 
better clinical translation in the future. We do not underestimate the practical challenges such a 
statement results in but hope that by delineating some of the complexities and aligning them next to 
common perceptions of genetics will lead to intelligent international debate about consent and 
disclosure practices, long-term follow-up arrangements, appropriate communication with relatives and 
linkages between clinical practice and research.
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